Table of Contents Author Guidelines Submit a Manuscript
Stem Cells International
Volume 2017, Article ID 9640108, 12 pages
https://doi.org/10.1155/2017/9640108
Review Article

Cellular Therapeutics for Heart Failure: Focus on Mesenchymal Stem Cells

1Department of Medicine, University of Arizona, Tucson, AZ, USA
2Division of Cardiology, Scripps Clinic, La Jolla, CA, USA
3Department of Physiology, University of Arizona, Tucson, AZ, USA
4Department of Immunobiology, University of Arizona, Tucson, AZ, USA
5Section of Cardiology, Southern Arizona Veterans Health Affairs System, Tucson, AZ, USA
6Sarver Heart Center, University of Arizona, Tucson, AZ, USA

Correspondence should be addressed to Amitabh C. Pandey; gro.htlaehsppircs@hbatima.yednap and Elizabeth Juneman; ude.anozira.chs@namenuje

Received 25 May 2017; Revised 31 July 2017; Accepted 14 August 2017; Published 17 December 2017

Academic Editor: Bojan Vrtovec

Copyright © 2017 Amitabh C. Pandey et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. A. Heidenreich, N. M. Albert, L. A. Allen et al., “Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association,” Circulation Heart Failure, vol. 6, pp. 606–619, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. A. H. Maass, K. Vernooy, S. C. Wijers et al., “Refining success of cardiac resynchronization therapy using a simple score predicting the amount of reverse ventricular remodelling: results from the markers and response to CRT (MARC) study,” Europace, 2017. View at Publisher · View at Google Scholar
  3. A. C. Pandey, J. A. Semon, D. Kaushal et al., “MicroRNA profiling reveals age-dependent differential expression of nuclear factor κB and mitogen-activated protein kinase in adipose and bone marrow-derived human mesenchymal stem cells,” Stem Cell Research & Therapy, vol. 2, no. 6, p. 49, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. D. J. Prockop, “Repair of tissues by adult stem/progenitor cells (MSCs): controversies, myths, and changing paradigms,” Molecular Therapy, vol. 17, no. 6, pp. 939–946, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. L. A. Ortiz, M. Dutreil, C. Fattman et al., “Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 26, pp. 11002–11007, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. M. P. De Miguel, S. Fuentes-Julian, A. Blazquez-Martinez et al., “Immunosuppressive properties of mesenchymal stem cells: advances and applications,” Current Molecular Medicine, vol. 12, no. 5, pp. 574–591, 2012. View at Google Scholar
  7. J. S. Da Silva and J. M. Hare, “Cell-based therapies for myocardial repair: emerging role for bone marrow-derived mesenchymal stem cells (MSCs) in the treatment of the chronically injured heart,” Methods in Molecular Biology, vol. 1037, pp. 145–163, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. E. Ratcliffe, R. J. Thomas, and D. J. Williams, “Current understanding and challenges in bioprocessing of stem cell-based therapies for regenerative medicine,” British Medical Bulletin, vol. 100, pp. 137–155, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. A. J. Friedenstein, J. F. Gorskaja, and N. N. Kulagina, “Fibroblast precursors in normal and irradiated mouse hematopoietic organs,” Experimental Hematology, vol. 4, no. 5, pp. 267–274, 1976. View at Google Scholar
  10. C. De Bari, F. Dell'Accio, P. Tylzanowski, and F. P. Luyten, “Multipotent mesenchymal stem cells from adult human synovial membrane,” Arthritis and Rheumatism, vol. 44, no. 8, pp. 1928–1942, 2001. View at Google Scholar
  11. A. Erices, P. Conget, and J. J. Minguell, “Mesenchymal progenitor cells in human umbilical cord blood,” British Journal of Haematology, vol. 109, no. 1, pp. 235–242, 2000. View at Google Scholar
  12. M. J. Hoogduijn, M. J. Crop, A. M. Peeters et al., “Human heart, spleen, and perirenal fat-derived mesenchymal stem cells have immunomodulatory capacities,” Stem Cells and Development, vol. 16, no. 4, pp. 597–604, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. P. S. In't Anker, S. A. Scherjon, C. Kleijburg-van der Keur et al., “Amniotic fluid as a novel source of mesenchymal stem cells for therapeutic transplantation,” Blood, vol. 102, no. 4, pp. 1548-1549, 2003. View at Google Scholar
  14. S. Kadiyala, R. G. Young, M. A. Thiede, and S. P. Bruder, “Culture expanded canine mesenchymal stem cells possess osteochondrogenic potential in vivo and in vitro,” Cell Transplantation, vol. 6, no. 2, pp. 125–134, 1997. View at Google Scholar
  15. P. A. Zuk, M. Zhu, P. Ashjian et al., “Human adipose tissue is a source of multipotent stem cells,” Molecular Biology of the Cell, vol. 13, no. 12, pp. 4279–4295, 2002. View at Publisher · View at Google Scholar · View at Scopus
  16. D. G. Phinney and D. J. Prockop, “Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair--current views,” Stem Cells, vol. 25, no. 11, pp. 2896–2902, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. C. Sanina and J. M. Hare, “Mesenchymal stem cells as a biological drug for heart disease: where are we with cardiac cell-based therapy?” Circulation Research, vol. 117, no. 3, pp. 229–233, 2015. View at Publisher · View at Google Scholar · View at Scopus
  18. W. T. Tse, J. D. Pendleton, W. M. Beyer, M. C. Egalka, and E. C. Guinan, “Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation,” Transplantation, vol. 75, no. 3, pp. 389–397, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. S. C. Hung, R. R. Pochampally, S. C. Chen, S. C. Hsu, and D. J. Prockop, “Angiogenic effects of human multipotent stromal cell conditioned medium activate the PI3K-Akt pathway in hypoxic endothelial cells to inhibit apoptosis, increase survival, and stimulate angiogenesis,” Stem Cells, vol. 25, no. 9, pp. 2363–2370, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. J. K. Biehl and B. Russell, “Introduction to stem cell therapy,” The Journal of Cardiovascular Nursing, vol. 24, no. 2, pp. 98–103, 2009, quiz 104-105. View at Publisher · View at Google Scholar
  21. D. J. Prockop, ““Stemness” does not explain the repair of many tissues by mesenchymal stem/multipotent stromal cells (MSCs),” Clinical Pharmacology and Therapeutics, vol. 82, no. 3, pp. 241–243, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. K. G. Shyu, B. W. Wang, H. F. Hung, C. C. Chang, and D. T. Shih, “Mesenchymal stem cells are superior to angiogenic growth factor genes for improving myocardial performance in the mouse model of acute myocardial infarction,” Journal of Biomedical Science, vol. 13, no. 1, pp. 47–58, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Bujak and N. G. Frangogiannis, “The role of IL-1 in the pathogenesis of heart disease,” Archivum Immunologiae et Therapiae Experimentalis (Warsz), vol. 57, no. 3, pp. 165–176, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. B. W. Van Tassell, R. A. Arena, S. Toldo et al., “Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure,” PLoS One, vol. 7, no. 3, article e33438, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. K. S. Telukuntla, V. Y. Suncion, I. H. Schulman, and J. M. Hare, “The advancing field of cell-based therapy: insights and lessons from clinical trials,” Journal of the American Heart Association, vol. 2, no. 5, article e000338, 2013. View at Publisher · View at Google Scholar
  26. P. R. Vulliet, M. Greeley, S. M. Halloran, K. A. MacDonald, and M. D. Kittleson, “Intra-coronary arterial injection of mesenchymal stromal cells and microinfarction in dogs,” Lancet, vol. 363, no. 9411, pp. 783-784, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. R. H. Lee, A. A. Pulin, M. J. Seo et al., “Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6,” Cell Stem Cell, vol. 5, no. 1, pp. 54–63, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. L. Li, S. Zhang, Y. Zhang, B. Yu, Y. Xu, and Z. Guan, “Paracrine action mediate the antifibrotic effect of transplanted mesenchymal stem cells in a rat model of global heart failure,” Molecular Biology Reports, vol. 36, no. 4, pp. 725–731, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. T. Freyman, G. Polin, H. Osman et al., “A quantitative, randomized study evaluating three methods of mesenchymal stem cell delivery following myocardial infarction,” European Heart Journal, vol. 27, no. 9, pp. 1114–1122, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. J. D. Richardson, A. G. Bertaso, P. J. Psaltis et al., “Impact of timing and dose of mesenchymal stromal cell therapy in a preclinical model of acute myocardial infarction,” Journal of Cardiac Failure, vol. 19, no. 5, pp. 342–353, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. K. E. Hatzistergos, H. Quevedo, B. N. Oskouei et al., “Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation,” Circulation Research, vol. 107, no. 7, pp. 913–922, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. J. M. Hare, J. E. Fishman, G. Gerstenblith et al., “Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial,” The Journal of the American Medical Association, vol. 308, no. 22, pp. 2369–2379, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. V. L. Roger, A. S. Go, D. M. Lloyd-Jones et al., “Heart disease and stroke statistics--2012 update: a report from the American Heart Association,” Circulation, vol. 125, no. 1, pp. e2–e220, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. L. W. Miller and E. D. Missov, “Epidemiology of heart failure,” Cardiology Clinics, vol. 19, no. 4, pp. 547–555, 2001. View at Google Scholar
  35. A. M. Katz, “The “modern” view of heart failure: how did we get here?” Circulation: Heart Failure, vol. 1, no. 1, pp. 63–71, 2008. View at Publisher · View at Google Scholar
  36. A. Abbate, B. W. Van Tassell, I. M. Seropian et al., “Interleukin-1β modulation using a genetically engineered antibody prevents adverse cardiac remodelling following acute myocardial infarction in the mouse,” European Journal of Heart Failure, vol. 12, no. 4, pp. 319–322, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. M. Bujak, M. Dobaczewski, K. Chatila et al., “Interleukin-1 receptor type I signaling critically regulates infarct healing and cardiac remodeling,” The American Journal of Pathology, vol. 173, no. 1, pp. 57–67, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. C. Freund, R. Schmidt-Ullrich, A. Baurand et al., “Requirement of nuclear factor-κB in angiotensin II- and isoproterenol-induced cardiac hypertrophy in vivo,” Circulation, vol. 111, no. 18, pp. 2319–2325, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. J. Heineke and J. D. Molkentin, “Regulation of cardiac hypertrophy by intracellular signalling pathways,” Nature Reviews Molecular Cell Biology, vol. 7, no. 8, pp. 589–600, 2006. View at Google Scholar
  40. M. Attisani, P. Centofanti, M. La Torre et al., “Advanced heart failure in critical patients (INTERMACS 1 and 2 levels): ventricular assist devices or emergency transplantation?” Interactive Cardiovascular and Thoracic Surgery, vol. 15, no. 4, pp. 678–684, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. N. Garg, A. Senthilkumar, M. B. Nusair, N. Goyal, R. K. Garg, and M. A. Alpert, “Heart failure with a normal left ventricular ejection fraction: epidemiology, pathophysiology, diagnosis and management,” The American Journal of the Medical Sciences, vol. 346, no. 2, pp. 129–136, 2013. View at Publisher · View at Google Scholar · View at Scopus
  42. F. Kamdar, R. John, P. Eckman, M. Colvin-Adams, S. J. Shumway, and K. Liao, “Postcardiac transplant survival in the current era in patients receiving continuous-flow left ventricular assist devices,” The Journal of Thoracic and Cardiovascular Surgery, vol. 145, no. 2, pp. 575–581, 2013. View at Publisher · View at Google Scholar · View at Scopus
  43. F. H. Verbrugge, P. De Vusser, M. Rivero-Ayerza et al., “Cardiac resynchronization therapy with or without defibrillator: experience from a high-volume Belgian implantation centre,” Acta Cardiologica, vol. 68, no. 1, pp. 37–45, 2013. View at Publisher · View at Google Scholar · View at Scopus
  44. M. J. Lenzen, E. Boersma, W. J. Reimer et al., “Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure,” European Heart Journal, vol. 26, no. 24, pp. 2706–2713, 2005. View at Publisher · View at Google Scholar · View at Scopus
  45. J. M. Hare, “Translational development of mesenchymal stem cell therapy for cardiovascular diseases,” Texas Heart Institute Journal, vol. 36, no. 2, pp. 145–147, 2009. View at Google Scholar
  46. B. Trachtenberg, D. L. Velazquez, A. R. Williams et al., “Rationale and design of the transendocardial injection of autologous human cells (bone marrow or mesenchymal) in chronic ischemic left ventricular dysfunction and heart failure secondary to myocardial infarction (TAC-HFT) trial: a randomized, double-blind, placebo-controlled study of safety and efficacy,” American Heart Journal, vol. 161, no. 3, pp. 487–493, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. J. M. Hare, D. L. DiFede, A. C. Rieger et al., “Randomized comparison of allogeneic versus autologous mesenchymal stem cells for nonischemic dilated cardiomyopathy: POSEIDON-DCM trial,” Journal of the American College of Cardiology, vol. 69, no. 5, pp. 526–537, 2017. View at Publisher · View at Google Scholar
  48. A. N. Patel, T. D. Henry, A. A. Quyyumi et al., “Ixmyelocel-T for patients with ischaemic heart failure: a prospective randomised double-blind trial,” Lancet, vol. 387, no. 10036, pp. 2412–2421, 2016. View at Publisher · View at Google Scholar · View at Scopus
  49. L. C. Amado, A. P. Saliaris, K. H. Schuleri et al., “Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 32, pp. 11474–11479, 2005. View at Google Scholar
  50. J. M. Hare, J. H. Traverse, T. D. Henry et al., “A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction,” Journal of the American College of Cardiology, vol. 54, no. 24, pp. 2277–2286, 2009. View at Publisher · View at Google Scholar · View at Scopus
  51. H. C. Quevedo, K. E. Hatzistergos, B. N. Oskouei et al., “Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trilineage differentiating capacity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 33, pp. 14022–14027, 2009. View at Publisher · View at Google Scholar · View at Scopus
  52. K. H. Schuleri, L. C. Amado, A. J. Boyle et al., “Early improvement in cardiac tissue perfusion due to mesenchymal stem cells,” American Journal of Physiology - Heart and Circulatory Physiology, vol. 294, no. 5, pp. H2002–H2011, 2008. View at Publisher · View at Google Scholar · View at Scopus
  53. G. V. Silva, S. Litovsky, J. A. Assad et al., “Mesenchymal stem cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a canine chronic ischemia model,” Circulation, vol. 111, no. 2, pp. 150–156, 2005. View at Publisher · View at Google Scholar · View at Scopus
  54. J. A. Dixon, R. C. Gorman, R. E. Stroud et al., “Mesenchymal cell transplantation and myocardial remodeling after myocardial infarction,” Circulation, vol. 120, Supplement 11, pp. S220–S229, 2009. View at Publisher · View at Google Scholar · View at Scopus
  55. Y. Y. Du, S. H. Zhou, T. Zhou et al., “Immuno-inflammatory regulation effect of mesenchymal stem cell transplantation in a rat model of myocardial infarction,” Cytotherapy, vol. 10, no. 5, pp. 469–478, 2008. View at Publisher · View at Google Scholar · View at Scopus
  56. S. Ishikane, K. Yamahara, M. Sada et al., “Allogeneic administration of fetal membrane-derived mesenchymal stem cells attenuates acute myocarditis in rats,” Journal of Molecular and Cellular Cardiology, vol. 49, no. 5, pp. 753–761, 2010. View at Publisher · View at Google Scholar · View at Scopus
  57. C. Schneider, K. Jaquet, S. Geidel et al., “Transplantation of bone marrow-derived stem cells improves myocardial diastolic function: strain rate imaging in a model of hibernating myocardium,” Journal of the American Society of Echocardiography, vol. 22, no. 10, pp. 1180–1189, 2009. View at Publisher · View at Google Scholar · View at Scopus
  58. A. I. Caplan and J. E. Dennis, “Mesenchymal stem cells as trophic mediators,” Journal of Cellular Biochemistry, vol. 98, no. 5, pp. 1076–1084, 2006. View at Publisher · View at Google Scholar · View at Scopus
  59. T. Nakamura, S. Mizuno, K. Matsumoto, Y. Sawa, H. Matsuda, and T. Nakamura, “Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF,” The Journal of Clinical Investigation, vol. 106, no. 12, pp. 1511–1519, 2000. View at Publisher · View at Google Scholar
  60. D. M. Pedrotty and L. E. Niklason, “Angiogenesis therapies for cardiovascular disease,” Current Opinion in Anaesthesiology, vol. 16, no. 1, pp. 3–9, 2003. View at Google Scholar
  61. S. Sadat, S. Gehmert, Y. H. Song et al., “The cardioprotective effect of mesenchymal stem cells is mediated by IGF-I and VEGF,” Biochemical and Biophysical Research Communications, vol. 363, no. 3, pp. 674–679, 2007. View at Publisher · View at Google Scholar · View at Scopus
  62. K. Urbanek, M. Rota, S. Cascapera et al., “Cardiac stem cells possess growth factor-receptor systems that after activation regenerate the infarcted myocardium, improving ventricular function and long-term survival,” Circulation Research, vol. 97, no. 7, pp. 663–673, 2005. View at Publisher · View at Google Scholar · View at Scopus
  63. F. Ezquer, J. Gutierrez, M. Ezquer, C. Caglevic, H. C. Salgado, and S. D. Calligaris, “Mesenchymal stem cell therapy for doxorubicin cardiomyopathy: hopes and fears,” Stem Cell Research & Therapy, vol. 6, p. 116, 2015. View at Publisher · View at Google Scholar · View at Scopus
  64. V. Jeevanantham, M. Butler, A. Saad, A. Abdel-Latif, E. K. Zuba-Surma, and B. Dawn, “Adult bone marrow cell therapy improves survival and induces long-term improvement in cardiac parameters: a systematic review and meta-analysis,” Circulation, vol. 126, no. 5, pp. 551–568, 2012. View at Publisher · View at Google Scholar · View at Scopus
  65. S. Chen, Z. Liu, N. Tian et al., “Intracoronary transplantation of autologous bone marrow mesenchymal stem cells for ischemic cardiomyopathy due to isolated chronic occluded left anterior descending artery,” The Journal of Invasive Cardiology, vol. 18, no. 11, pp. 552–556, 2006. View at Google Scholar
  66. A. B. Mathiasen, M. Haack-Sorensen, and J. Kastrup, “Mesenchymal stromal cells for cardiovascular repair: current status and future challenges,” Future Cardiology, vol. 5, no. 6, pp. 605–617, 2009. View at Publisher · View at Google Scholar · View at Scopus
  67. J. Bartunek, A. Behfar, D. Dolatabadi et al., “Cardiopoietic stem cell therapy in heart failure: the C-CURE (cardiopoietic stem cell therapy in heart failure) multicenter randomized trial with lineage-specified biologics,” Journal of the American College of Cardiology, vol. 61, no. 23, pp. 2329–2338, 2013. View at Publisher · View at Google Scholar · View at Scopus
  68. A. B. Mathiasen, E. Jorgensen, A. A. Qayyum, M. Haack-Sorensen, A. Ekblond, and J. Kastrup, “Rationale and design of the first randomized, double-blind, placebo-controlled trial of intramyocardial injection of autologous bone-marrow derived mesenchymal stromal cells in chronic ischemic heart failure (MSC-HF trial),” American Heart Journal, vol. 164, no. 3, pp. 285–291, 2012. View at Publisher · View at Google Scholar · View at Scopus
  69. E. C. Perin, G. V. Silva, T. D. Henry et al., “A randomized study of transendocardial injection of autologous bone marrow mononuclear cells and cell function analysis in ischemic heart failure (FOCUS-HF),” American Heart Journal, vol. 161, no. 6, pp. 1078–1087.e3, 2011. View at Google Scholar
  70. D. D. Ascheim, A. C. Gelijns, D. Goldstein et al., “Mesenchymal precursor cells as adjunctive therapy in recipients of contemporary left ventricular assist devices,” Circulation, vol. 129, no. 22, pp. 2287–2296, 2014. View at Publisher · View at Google Scholar · View at Scopus
  71. S. Li, X. Wang, J. Li et al., “Advances in the treatment of ischemic diseases by mesenchymal stem cells,” Stem Cells International, vol. 2016, Article ID 5896061, 11 pages, 2016. View at Publisher · View at Google Scholar · View at Scopus
  72. J. Butler, S. E. Epstein, S. J. Greene et al., “Intravenous allogeneic mesenchymal stem cells for nonischemic cardiomyopathy: safety and efficacy results of a phase II-A randomized trial,” Circulation Research, vol. 120, no. 2, pp. 332–340, 2017. View at Publisher · View at Google Scholar · View at Scopus
  73. A. W. Heldman, D. L. DiFede, J. E. Fishman et al., “Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial,” The Journal of the American Medical Association, vol. 311, no. 1, pp. 62–73, 2014. View at Publisher · View at Google Scholar · View at Scopus
  74. A. N. Patel, S. Mittal, G. Turan et al., “REVIVE trial: retrograde delivery of autologous bone marrow in patients with heart failure,” Stem Cells Translational Medicine, vol. 4, no. 9, pp. 1021–1027, 2015. View at Publisher · View at Google Scholar · View at Scopus
  75. S. L. Chen, W. W. Fang, F. Ye et al., “Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction,” The American Journal of Cardiology, vol. 94, no. 1, pp. 92–95, 2004. View at Publisher · View at Google Scholar · View at Scopus
  76. A. B. Mathiasen, A. A. Qayyum, E. Jorgensen et al., “Bone marrow-derived mesenchymal stromal cell treatment in patients with severe ischaemic heart failure: a randomized placebo-controlled trial (MSC-HF trial),” European Heart Journal, vol. 36, no. 27, pp. 1744–1753, 2015. View at Publisher · View at Google Scholar · View at Scopus
  77. E. C. Perin, J. T. Willerson, C. J. Pepine et al., “Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial,” The Journal of the American Medical Association, vol. 307, no. 16, pp. 1717–1726, 2012. View at Publisher · View at Google Scholar · View at Scopus
  78. K. H. Schuleri, G. S. Feigenbaum, M. Centola et al., “Autologous mesenchymal stem cells produce reverse remodelling in chronic ischaemic cardiomyopathy,” European Heart Journal, vol. 30, no. 22, pp. 2722–2732, 2009. View at Publisher · View at Google Scholar · View at Scopus
  79. X. Wang, M. N. Jameel, Q. Li et al., “Stem cells for myocardial repair with use of a transarterial catheter,” Circulation, vol. 120, Supplement 11, pp. S238–S246, 2009. View at Publisher · View at Google Scholar · View at Scopus
  80. E. Mathieu, G. Lamirault, C. Toquet et al., “Intramyocardial delivery of mesenchymal stem cell-seeded hydrogel preserves cardiac function and attenuates ventricular remodeling after myocardial infarction,” PLoS One, vol. 7, no. 12, article e51991, 2012. View at Publisher · View at Google Scholar · View at Scopus
  81. B. Follin, M. Juhl, S. Cohen et al., “Human adipose-derived stromal cells in a clinically applicable injectable alginate hydrogel: phenotypic and immunomodulatory evaluation,” Cytotherapy, vol. 17, no. 8, pp. 1104–1118, 2015. View at Publisher · View at Google Scholar · View at Scopus
  82. R. D. Levit, N. Landazuri, E. A. Phelps et al., “Cellular encapsulation enhances cardiac repair,” Journal of the American Heart Association, vol. 2, no. 5, article e000367, 2013. View at Publisher · View at Google Scholar
  83. B. Assmus, U. Fischer-Rasokat, J. Honold et al., “Transcoronary transplantation of functionally competent BMCs is associated with a decrease in natriuretic peptide serum levels and improved survival of patients with chronic postinfarction heart failure: results of the TOPCARE-CHD registry,” Circulation Research, vol. 100, no. 8, pp. 1234–1241, 2007. View at Publisher · View at Google Scholar · View at Scopus
  84. B. Assmus, D. H. Walter, F. H. Seeger et al., “Effect of shock wave-facilitated intracoronary cell therapy on LVEF in patients with chronic heart failure: the CELLWAVE randomized clinical trial,” The Journal of the American Medical Association, vol. 309, no. 15, pp. 1622–1631, 2013. View at Publisher · View at Google Scholar · View at Scopus
  85. E. A. Bocchi, F. Bacal, G. Guimaraes et al., “Granulocyte-colony stimulating factor or granulocyte-colony stimulating factor associated to stem cell intracoronary infusion effects in non ischemic refractory heart failure,” International Journal of Cardiology, vol. 138, no. 1, pp. 94–97, 2010. View at Publisher · View at Google Scholar · View at Scopus
  86. L. A. Sanchez, C. E. Guerrero-Beltran, A. M. Cordero-Reyes, G. Garcia-Rivas, and G. Torre-Amione, “Use of stem cells in heart failure treatment: where we stand and where we are going,” Methodist DeBakey Cardiovascular Journal, vol. 9, no. 4, pp. 195–200, 2013. View at Google Scholar
  87. J. Lancaster, E. Juneman, T. Hagerty et al., “Viable fibroblast matrix patch induces angiogenesis and increases myocardial blood flow in heart failure after myocardial infarction,” Tissue Engineering, Part A, vol. 16, no. 10, pp. 3065–3073, 2010. View at Google Scholar
  88. H. M. Thai, E. Juneman, J. Lancaster et al., “Implantation of a three-dimensional fibroblast matrix improves left ventricular function and blood flow after acute myocardial infarction,” Cell Transplantation, vol. 18, no. 3, pp. 283–295, 2009. View at Google Scholar